High or low? Assessing disease risk in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Biomarkers

Background:

• Significant survival improvements in multiple myeloma (MM) over 20 years due to novel therapies like immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.
• Despite therapeutic advances, a subset of MM patients still faces aggressive disease, high morbidity, and early mortality.
• Current prognostic biomarkers and staging systems have limitations in accurately assessing risk due to variable prognostic value.

Purpose of the Study:

• To emphasize the need for dynamic risk assessment in multiple myeloma.
• To highlight the importance of understanding biological and prognostic implications of various biomarkers.
• To guide management strategies for improving survival and quality of life across the MM risk spectrum.

Main Methods:

• Review of clinical, genomic, and response-based biomarkers in multiple myeloma.
• Analysis of the evolving landscape of novel therapies and their impact on patient responses.
• Evaluation of current prognostication tools and their limitations.

Main Results:

• Novel therapies have led to prolonged survival for many MM patients, with over 10 years post-diagnosis being common.
• A significant patient subset still experiences aggressive disease courses.
• Accurate risk stratification is challenging due to numerous biomarkers with differing prognostic significance.

Conclusions:

• Risk assessment in multiple myeloma is a dynamic process requiring continuous reevaluation.
• Understanding clinical, genomic, and response biomarkers is essential for effective management.
• Risk and response-adapted strategies are key to optimizing survival and quality of life for all MM patients.